Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 9:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–94 of 94 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pneumococcal 13-valent Conjugate Vaccine Clear all
Recruiting Phase 1Phase 2 Interventional

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

NCT03942328
View directory record Official record
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Atezolizumab, Bevacizumab, External Beam Radiation Therapy, Pheresis, Pneumococcal 13-valent Conjugate Vaccine, Therapeutic Autologous Dendritic Cells, Durvalumab, Esophagogastroduodenoscopy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biopsy Procedure, Biospecimen Collection
Biological · Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 9, 2026, 9:22 PM EDT
Completed No phase listed Observational Results available

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

NCT05794191
View directory record Official record
Conditions
HIV, Pneumonia, Infections, Pneumococcal
Interventions
Vaccine Administration
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
350,399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

NCT03691610
View directory record Official record
Conditions
Healthy Volunteers (Meningococcal Infection)
Interventions
Meningococcal Polysaccharide (Serogroups A,C,Y and W) Tetanus Toxoid Conjugate vaccine MenACYW conjugate vaccine, Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine, Meningococcal Polysaccharide (serogroups A,C,Y and W-135) Diphtheria Toxoid Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, inactivated Poliovirus and Haemophilus b Conjugate Vaccine, Diphtheria and Tetanus Toxoids and Acellular Pertussis, Hepatitis B and Inactivated Poliovirus Vaccine, Haemophilus b Conjugate Vaccine, Pneumococcal 13-valent Conjugate Vaccine, Rotavirus Vaccine, Live, Oral, Pentavalent, Hepatitis B Vaccine, Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 19 Months
Enrollment
950 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
45
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines

NCT03104075
View directory record Official record
Conditions
Pneumonia, Aging
Interventions
Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein, Pneumococcal Vaccine Polyvalent
Biological
Lead sponsor
The Jackson Laboratory
Other
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

NCT03565900
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
3 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Palo Alto, California • Aurora, Colorado • Gainesville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health

NCT03819049
View directory record Official record
Conditions
Extraintestinal Pathogenic Escherichia Coli Prevention
Interventions
ExPEC10V, ExPEC4V, Prevnar 13, Placebo
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
60 Years and older
Enrollment
836 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
12
States / cities
Huntsville, Alabama • Melbourne, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

NCT02987972
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114 Lot 1, V114 Lot 2, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,051 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
30
States / cities
Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

NCT03313037
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13, PPSV23, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
14
States / cities
Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

NCT03547167
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,515 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
38
States / cities
Chinle, Arizona • Fort Defiance, Arizona • Glendale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

NCT03207750
View directory record Official record
Conditions
Rotavirus Infection, Rotavirus Vaccines
Interventions
Rotarix, Pediarix, Hiberix, Prevenar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
47
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 9, 2026, 9:22 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age

NCT06740630
View directory record Official record
Conditions
Chickenpox
Interventions
Investigational varicella vaccine_Lot 1, Investigational varicella vaccine_Lot 2, Investigational varicella vaccine_Lot 3, Marketed varicella vaccine_Lot 1, Marketed varicella vaccine_Lot 2, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
1,840 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
59
States / cities
Mobile, Alabama • Hot Springs, Arkansas • Sherwood, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)

NCT06698198
View directory record Official record
Conditions
Pneumococcal Immunization
Interventions
Pneumococcal Conjugate Vaccine, Prevnar 13®
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
19 Years to 49 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Metairie, Louisiana • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

NCT01000311
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenACWY-CRM, DTaP-IPV/Hib, HBV, PCV, MMR
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
55 Days to 89 Days
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
42
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 2 Interventional

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02518555
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment, Trivalent Influenza Vaccine
Biological · Drug · Other
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

NCT03893448
View directory record Official record
Conditions
Pneumococcal Infections, Pneumococcal Vaccines
Interventions
V114, Prevnar 13™, RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, MMR II™, VARIVAX™, HIBERIX™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
1,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
66
States / cities
Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

NCT02124161
View directory record Official record
Conditions
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE
Interventions
13-valent pneumococcal conjugate vaccine, Seasonal Inactivated Influenza Vaccine, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
44
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

NCT03642847
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Prevnar 13, multivalent pneumococcal conjugate formulation 1, multivalent pneumococcal conjugate formulation 2
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Garden Grove, California • Long Beach, California • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 9, 2026, 9:22 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers

NCT01732198
View directory record Official record
Conditions
Infectious Disease
Interventions
NU300, ActHIB, Prevnar 13
Biological
Lead sponsor
Nuron Biotech Inc.
Industry
Eligibility
12 Months to 15 Months
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Oakland, California • Bardstown, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 23, 2013 · Synced Oct 9, 2026, 9:22 PM EDT
Recruiting Phase 4 Interventional

Vaccine Responses in Patients With B Cell Malignancies

NCT05170399
View directory record Official record
Conditions
Lymphoma
Interventions
AREXVY, ABRYSVO, PREVNAR 20, PNEUMOVAX 23, Heplisav -B, PREVNAR 13, Shingrix
Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 90 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2036
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Activated White Blood Cells With ASCT for Newly Diagnosed Multiple Myeloma

NCT00566098
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
MILs, Melphalan, PCV13
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)

NCT03731182
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
5 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Wilmington, Delaware • Atlanta, Georgia • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2021 · Synced Oct 9, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older

NCT03439657
View directory record Official record
Conditions
Herpes Zoster
Interventions
HZ/su vaccine GSK1437173A, Prevenar13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
913 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
3
States / cities
Marlborough, Massachusetts • Salisbury, North Carolina • Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 11, 2022 · Synced Oct 9, 2026, 9:22 PM EDT